度拉糖肽-话题@MedSci

#度拉糖肽#

12篇内容 | 1668人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2211765, encodeId=ff502211e6528, content=<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a> <a href='/topic/show?id=ad0510683856' target=_blank style='color:#2F92EE;'>#替尔泊肽#</a>, objectTitle=Front Pharmacol：接受血液透析的2型糖尿病患者从度拉糖肽过渡到替尔泊肽可以改善血糖控制, objectType=article, longId=831940, objectId=d2ca8319401d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240626/1719392643253_92910.jpg, objectUrl=/article/show_article.do?id=d2ca8319401d, replyNumber=0, likeNumber=85, createdTime=2024-06-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d2ca8319401d, moduleTitle=Front Pharmacol：接受血液透析的2型糖尿病患者从度拉糖肽过渡到替尔泊肽可以改善血糖控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2ca8319401d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1322666, encodeId=2fd31322666e5, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=Diabetes Obes Metab：根据基线糖化血红蛋白(HbA1c)亚组扩大度拉糖肽剂量范围的血糖疗效, objectType=article, longId=220009, objectId=8cbd220009c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cbd220009c6, replyNumber=0, likeNumber=68, createdTime=2021-11-10, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cbd220009c6, moduleTitle=Diabetes Obes Metab：根据基线糖化血红蛋白(HbA1c)亚组扩大度拉糖肽剂量范围的血糖疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cbd220009c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322665, encodeId=e1031322665ef, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=Diabetes Care：度拉糖肽明显改善肥胖和2型糖尿病患者肝脏代谢, objectType=article, longId=213294, objectId=52a4213294e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52a4213294e8, replyNumber=0, likeNumber=81, createdTime=2021-06-28, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52a4213294e8, moduleTitle=Diabetes Care：度拉糖肽明显改善肥胖和2型糖尿病患者肝脏代谢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52a4213294e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322664, encodeId=330f1322664fd, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=JCEM：度拉糖肽对老年患者疗效和安全性分析, objectType=article, longId=206871, objectId=25072068e1d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25072068e1d7, replyNumber=0, likeNumber=69, createdTime=2021-02-08, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25072068e1d7, moduleTitle=JCEM：度拉糖肽对老年患者疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25072068e1d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322663, encodeId=7711132266346, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=礼来度易达(R)（度拉糖肽）正式在中国上市, objectType=article, longId=168670, objectId=db941686e018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db941686e018, replyNumber=0, likeNumber=0, createdTime=2019-06-19, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db941686e018, moduleTitle=礼来度易达(R)（度拉糖肽）正式在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db941686e018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322662, encodeId=78a91322662f4, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161211, objectId=849816121109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849816121109, replyNumber=0, likeNumber=89, createdTime=2019-02-28, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849816121109, moduleTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849816121109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322661, encodeId=abaa13226611d, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161199, objectId=4d8e16119952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8e16119952, replyNumber=0, likeNumber=88, createdTime=2019-02-28, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8e16119952, moduleTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8e16119952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322660, encodeId=399b1322660ff, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=度拉糖肽针对广泛人群2型糖尿病患者心血管事件减少显示优效：REWIND研究中，基线时确诊心血管疾病患者仅有31%, objectType=article, longId=152925, objectId=6cdc152925ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cdc152925ce, replyNumber=0, likeNumber=71, createdTime=2018-11-08, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cdc152925ce, moduleTitle=度拉糖肽针对广泛人群2型糖尿病患者心血管事件减少显示优效：REWIND研究中，基线时确诊心血管疾病患者仅有31%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cdc152925ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322659, encodeId=03f5132265953, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=ADA 2018：度拉糖肽治疗的糖尿病患者真实世界研究数据公布！, objectType=article, longId=142475, objectId=64f71424e57d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64f71424e57d, replyNumber=0, likeNumber=83, createdTime=2018-07-06, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64f71424e57d, moduleTitle=ADA 2018：度拉糖肽治疗的糖尿病患者真实世界研究数据公布！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64f71424e57d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322658, encodeId=b0851322658b1, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=Lancet diabetes endo：度拉糖肽作为SGLT2抑制剂的补充治疗，用于血糖控制效果欠佳的2型糖尿病患者的效果和安全性, objectType=article, longId=130540, objectId=df9e130540b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df9e130540b9, replyNumber=0, likeNumber=110, createdTime=2018-02-26, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df9e130540b9, moduleTitle=Lancet diabetes endo：度拉糖肽作为SGLT2抑制剂的补充治疗，用于血糖控制效果欠佳的2型糖尿病患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df9e130540b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322657, encodeId=75bc132265e74, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=Lancet Diabetes Endo：索马鲁肽对血糖控制和体重减轻的效果优于度拉糖肽, objectType=article, longId=128501, objectId=fce812850124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fce812850124, replyNumber=0, likeNumber=77, createdTime=2018-02-03, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fce812850124, moduleTitle=Lancet Diabetes Endo：索马鲁肽对血糖控制和体重减轻的效果优于度拉糖肽, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fce812850124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322656, encodeId=23e9132265614, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=Diabetes Obes Metab：降糖药度拉糖肽与利拉鲁肽比较, objectType=article, longId=61855, objectId=1c65618553c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c65618553c, replyNumber=0, likeNumber=66, createdTime=2016-01-09, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c65618553c, moduleTitle=Diabetes Obes Metab：降糖药度拉糖肽与利拉鲁肽比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c65618553c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322655, encodeId=4176132265589, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, objectTitle=FDA批准礼来糖尿病新药度拉糖肽（dulaglutide）上市每周只需一次, objectType=article, longId=40876, objectId=5298408e61a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5298408e61a, replyNumber=0, likeNumber=0, createdTime=2014-10-04, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5298408e61a, moduleTitle=FDA批准礼来糖尿病新药度拉糖肽（dulaglutide）上市每周只需一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5298408e61a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

度拉糖肽

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#2型糖尿病# #度拉糖肽# #替尔泊肽#

Front Pharmacol：接受血液透析的2型糖尿病患者从度拉糖肽过渡到替尔泊肽可以改善血糖控制

2024-06-26发表于上海

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

Diabetes Obes Metab：根据基线糖化血红蛋白(HbA1c)亚组扩大度拉糖肽剂量范围的血糖疗效

2021-11-10

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

Diabetes Care：度拉糖肽明显改善肥胖和2型糖尿病患者肝脏代谢

2021-06-28

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

JCEM：度拉糖肽对老年患者疗效和安全性分析

2021-02-08

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

礼来度易达(R)（度拉糖肽）正式在中国上市

2019-06-19

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

度拉糖肽针对广泛人群2型糖尿病患者心血管事件减少显示优效：REWIND研究中，基线时确诊心血管疾病患者仅有31%

2018-11-08

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

ADA 2018：度拉糖肽治疗的糖尿病患者真实世界研究数据公布！

2018-07-06

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

Lancet diabetes endo：度拉糖肽作为SGLT2抑制剂的补充治疗，用于血糖控制效果欠佳的2型糖尿病患者的效果和安全性

2018-02-26

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

Lancet Diabetes Endo：索马鲁肽对血糖控制和体重减轻的效果优于度拉糖肽

2018-02-03

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

Diabetes Obes Metab：降糖药度拉糖肽与利拉鲁肽比较

2016-01-09

xiaoyang_ambs (审核中...)

前往app查看评论内容

#度拉糖肽#

FDA批准礼来糖尿病新药度拉糖肽（dulaglutide）上市每周只需一次

2014-10-04

科室
- - 订阅+
  - 更多科室
工具
服务